Thank you so much. This is pertinent: The four

Quote:

---

The fourth thing that I'd like to say that we know about leronlimab that's not often discussed is that it has a high barrier resistance, which is unique and different than many of the antivirals for HIV, in that during the monotherapy studies, you know, we saw a lot of people who broke through early on, and Nader used to quote that 12-week threshold, but there were patients who, and many patients who either broke through it or particularly blipped after 12 weeks. And what was interesting to see is that if we just kept them on leronlimab I would say the majority of them, and the great majority of them, actually returned to undetectable on their own. So those were immune activation events where we were giving patients a drug that was only blocking HIV attachment. And as such, the virus was free to replicate and had these blips that were unacceptable to the treating community because at that point patients would be infectious. But I was surprised to see how many of those patients with blips re-suppressed on their own while on leronlimab indicating to me that it wasn't a problem of leronlimab resistance but rather the fact that leronlimab was just acting on the early part of the HIV viral life cycle. So those are the things we know. It's a good antiviral. It's safe. It's once a week dosing. It's got a good barrier resistance. And all of that relates to leronlimab as a competitive inhibitor of HIV attachment which is fine and it would be great if we'd been able to find another drug and find a niche within the HIV treatment landscape.

---